Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

55.6%

-30.9% vs industry average

Late-Stage Pipeline

78%

7 trials in Phase 3/4

Results Transparency

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 4

7(77.8%)

N/A

2(22.2%)

9Total

Phase 4(7)

N/A(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT02978456Not ApplicableCompleted

Quantitative Coronary Angiography Versus Intravascular Ultrasound GUIDancE for Drug-Eluting Stent Implantation

Role: lead

NCT04330079Phase 4Terminated

Effects of dapaglifloziN Therapy on Myocardial Perfusion Reserve in Prediabetic Patients With Stable coronarY Artery Disease

Role: lead

NCT03208465Phase 4Completed

Empagliflozin Versus Sitagliptin Therapy for Improvement of Myocardial Perfusion Reserve in Diabetic Patients With Coronary Artery Disease

Role: lead

NCT02105623Phase 4Terminated

EARly Prevention of aTHeroma Progression

Role: lead

NCT02378064Phase 4Completed

Comparison of Fimasartan Versus Amlodipine Therapy on Carotid PlaquE Inflammation

Role: lead

NCT02494284Phase 4Terminated

Short-Term Dual Antiplatelet and Maintenance CloPidogrel Therapy After Drug-Eluting Stent Implantation

Role: lead

NCT01905566Phase 4Completed

Comparison of Clopidogrel Versus Ticagrelor Therapy for Atherosclerotic Plaque Inflammation

Role: lead

NCT01515228Phase 4Completed

Comparison of Cilotax Stent and Everolimus -Eluting Stent With Diabetes Mellitus (ESSENCE-DM III)

Role: lead

NCT01665248Not ApplicableTerminated

Comparison of 18-F Sodium Fluoride Uptake in Culprit Plaques Between Acute Coronary Syndrome and Stable Angina

Role: lead

All 9 trials loaded